Crestor

AstraZeneca PLC
13 February 2003



                   AstraZeneca Submits Information Amendment
               For CRESTOR(R)(rosuvastatin calcium) NDA to FDA


AstraZeneca announced today the submission of an information amendment to its
New Drug Application (NDA) for CRESTOR(R) (rosuvastatin calcium) Tablets in
response to the US Food and Drug Administration (FDA) approvable letter of May
2002.

The additional data provide further support for the proposed use of CRESTOR(R)
Tablets for the treatment of patients for the management of
hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia.



13 February 2003



Media Enquiries:
Emily Denney, Tel: [phone]
Steve Brown, Tel: [phone]

Investor Relations:
Mina Blair Robinson, Tel: [phone]
Jonathan Hunt, Tel:  [phone]



-Ends-


                      This information is provided by RNS
            The company news service from the London Stock Exchange